LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 226,518 shares of common stock through Morgan Stanley & Co. LLC on 08/18/2025. The filing states an aggregate market value of $1,225,462.38 and reports 388,936,394 shares outstanding. The securities were acquired in a pre-IPO transaction on 06/10/2021, when 1,299,792 shares were obtained from the issuer; payment is noted as equity interests purchased pre-IPO. No sales by the reporting person in the past three months are disclosed. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
LifeStance Health Group, Inc. (LFST) filed a Form 144 disclosing a proposed sale of 3,214,648 shares of Common Stock through Morgan Stanley & Co. LLC on 08/18/2025 on NASDAQ, with an aggregate market value of $17,391,245.68. The shares were originally acquired 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc.; the filing reports total outstanding shares of 388,936,394. The filer certifies there is no undisclosed material adverse information and notes no securities were sold by the filer in the past three months.
LifeStance Health Group, Inc. (LFST) submitted a Form 144 notice for a proposed sale of securities under Rule 144. The filing shows 5,148,494 shares of Common Stock are planned to be sold through Morgan Stanley & Co. LLC on or about 08/18/2025, with an aggregate market value of $27,853,352.54 and 388,936,394 shares outstanding. The securities were acquired on 06/10/2021 in a pre-IPO transaction, totaling 29,542,786 shares acquired on that date. No securities were reported sold in the past three months. The filer certifies they do not possess undisclosed material adverse information about the issuer.
LifeStance Health Group, Inc. (LFST) filed a Form 144 reporting a proposed sale of 4,804 shares of common stock through Morgan Stanley & Co. LLC on approximately 08/18/2025. The filing lists an aggregate market value of $25,989.64 and indicates 388,936,394 shares outstanding. The shares were originally acquired on 06/10/2021 in a pre-IPO transaction from LifeStance Health Group Inc., with 27,568 shares noted as acquired at that time. No securities were reported sold in the past three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer and the notice is marked LIVE.
LifeStance Health Group, Inc. (LFST) Form 144 notifies the market of a proposed sale of 35,938 shares of common stock through Morgan Stanley & Co. LLC, with an aggregate market value of $194,424.58. The filing states the securities will be sold approximately on 08/18/2025 on NASDAQ and shows 388,936,394 shares outstanding. The shares were originally acquired 06/10/2021 in a pre-IPO transaction (206,219 shares acquired) from LifeStance Health Group Inc. No sales by the seller are reported in the past three months.
LifeStance Health Group, Inc. (LFST) filed a Form 144 notifying a proposed sale of 3,759 shares of Common Stock through Morgan Stanley & Co. LLC with an aggregate market value of $20,336.19. The filing lists approximately 388,936,394 shares outstanding and an approximate sale date of 08/18/2025.
The shares were originally acquired 06/10/2021 in pre-IPO transactions from LifeStance Health Group Inc.; the filer reported acquiring 21,572 shares on that date. The notice states there were no securities sold by the account in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kenneth A. Burdick, a director of LifeStance Health Group, Inc. (LFST), reported multiple open-market purchases of common stock on August 8 and August 11, 2025. The filings show acquisitions totaling 67,670 shares at prices between $4.30 and $4.54. After these transactions his reported direct beneficial ownership rose to 3,436,571 shares, and he also holds 46,511 shares indirectly through Burdick Family LLC.